To include your compound in the COVID-19 Resource Center, submit it here.

ADC reports Phase I data for ADCT-402 in NHL

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 68 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the dose-escalation portion of the Phase I

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE